Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
edp1503
- Development stage
- Phase 2
- Lead developer
- Evelo Biosciences
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EDP1503 is an orally delivered, non-live, monoclonal microbial candidate developed by Evelo Biosciences for the treatment of various advanced cancers. Originally licensed from the University of Chicago, the drug consists of a single strain of *Bifidobacterium animalis* subsp. *lactis*. It is designed to act on the small intestinal axis (SINTAX) to modulate the systemic immune system without being absorbed into the bloodstream. By interacting with immune cells in the small intestine, EDP1503 aims to induce a systemic pro-inflammatory response that enhances anti-tumor T-cell activity. It has been primarily investigated in Phase 1/2 clinical trials in combination with the PD-1 inhibitor pembrolizumab (Keytruda) to treat patients with microsatellite stable colorectal cancer (MSS CRC), triple-negative breast cancer (TNBC), and tumors that have relapsed following checkpoint inhibitor therapy.
- Other names
- EDP1503 monoclonal microbialEDP-1503 monoclonal microbialEDP 1503 monoclonal microbial
Beyond the preview
Go deeper on edp1503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on edp1503.